Northern Trust
RLMD icon

Northern Trust’s Relmada Therapeutics RLMD Stock Holding History

Northern Trust’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1M Sell
157,734
-7,719
-5% -$36.5K ﹤0.01% 3293
2025
Q4 		$799K Buy
165,453
+106,430
+180% +$357K ﹤0.01% 3475
2025
Q3 		$119K Sell
59,023
-548
-0.9% -$526 ﹤0.01% 4095
2025
Q2 		$35.8K Hold
59,571
– – ﹤0.01% 4285
2025
Q1 		$16.1K Sell
59,571
-24,711
-29% -$8.19K ﹤0.01% 4359
2024
Q4 		$43.8K Buy
84,282
+9,566
+13% +$23.3K ﹤0.01% 4278
2024
Q3 		$242K Sell
74,716
-4,259
-5% -$13.8K ﹤0.01% 3817
2024
Q2 		$237K Sell
78,975
-2,074
-3% -$7.5K ﹤0.01% 3806
2024
Q1 		$377K Sell
81,049
-15,218
-16% -$73.3K ﹤0.01% 3655
2023
Q4 		$399K Buy
96,267
+49,165
+104% +$146K ﹤0.01% 3619
2023
Q3 		$141K Sell
47,102
-348
-0.7% -$1.03K ﹤0.01% 3924
2023
Q2 		$117K Sell
47,450
-162,541
-77% -$449K ﹤0.01% 3995
2023
Q1 		$475K Sell
209,991
-18,358
-8% -$63.3K ﹤0.01% 3488
2022
Q4 		$797K Sell
228,349
-23,128
-9% -$203K ﹤0.01% 3345
2022
Q3 		$9.31M Buy
251,477
+1,406
+0.6% +$39K ﹤0.01% 2024
2022
Q2 		$4.75M Buy
250,071
+4,435
+2% +$96.7K ﹤0.01% 2552
2022
Q1 		$6.63M Buy
245,636
+71,704
+41% +$1.48M ﹤0.01% 2405
2021
Q4 		$3.92M Buy
173,932
+10,727
+7% +$239K ﹤0.01% 2838
2021
Q3 		$4.28M Buy
163,205
+6,807
+4% +$182K ﹤0.01% 2828
2021
Q2 		$5.01M Sell
156,398
-6,296
-4% -$219K ﹤0.01% 2837
2021
Q1 		$5.73M Sell
162,694
-10,274
-6% -$359K ﹤0.01% 2669
2020
Q4 		$5.55M Sell
172,968
-4,050
-2% -$139K ﹤0.01% 2626
2020
Q3 		$6.66M Sell
177,018
-5,305
-3% -$205K ﹤0.01% 2357
2020
Q2 		$8.16M Buy
182,323
+155,710
+585% +$6.58M ﹤0.01% 2224
2020
Q1 		$908K Buy
26,613
+2,332
+10% +$94K ﹤0.01% 3254
2019
Q4 		$947K Buy
+24,281
New +$738K ﹤0.01% 3417

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Northern Trust's RLMD Position: Q1 2026 in Review

Northern Trust reduced its Relmada Therapeutics (RLMD) stake by 4.7% in Q1 2026, selling an estimated $36.5K and leaving 157,734 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3293.

Northern Trust first reported a position in RLMD in Q4 2019 and has held it in 26 quarters since. The position peaked at $9.31M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Northern Trust held 157,734 shares of Relmada Therapeutics worth $1.1M as of Q1 2026.
  • Northern Trust sold 7,719 Relmada Therapeutics shares in Q1 2026, an estimated $36.5K.
  • Relmada Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3293 holding.
  • Northern Trust first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Northern Trust's Relmada Therapeutics position peaked at $9.31M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.